BR112014003501B1 - Anticorpo humanizado que se liga especificamente à integrina alfa-v beta-8, seu uso na redução da sinalização de tgfbeta, composição farmacêutica, bem como método para detectar a presença de uma célula que expressa alfa-v beta-8 - Google Patents

Anticorpo humanizado que se liga especificamente à integrina alfa-v beta-8, seu uso na redução da sinalização de tgfbeta, composição farmacêutica, bem como método para detectar a presença de uma célula que expressa alfa-v beta-8 Download PDF

Info

Publication number
BR112014003501B1
BR112014003501B1 BR112014003501-6A BR112014003501A BR112014003501B1 BR 112014003501 B1 BR112014003501 B1 BR 112014003501B1 BR 112014003501 A BR112014003501 A BR 112014003501A BR 112014003501 B1 BR112014003501 B1 BR 112014003501B1
Authority
BR
Brazil
Prior art keywords
antibody
seq
cell
αvβ8
antibodies
Prior art date
Application number
BR112014003501-6A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014003501A2 (pt
Inventor
Steven Nishimura
Jianlong Lou
Jody Lynn Baron
James Marks
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of BR112014003501A2 publication Critical patent/BR112014003501A2/pt
Publication of BR112014003501B1 publication Critical patent/BR112014003501B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112014003501-6A 2011-08-17 2012-08-17 Anticorpo humanizado que se liga especificamente à integrina alfa-v beta-8, seu uso na redução da sinalização de tgfbeta, composição farmacêutica, bem como método para detectar a presença de uma célula que expressa alfa-v beta-8 BR112014003501B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161524708P 2011-08-17 2011-08-17
US61/524,708 2011-08-17
US201261646111P 2012-05-11 2012-05-11
US61/646,111 2012-05-11
PCT/US2012/051373 WO2013026004A2 (en) 2011-08-17 2012-08-17 Antibodies that bind integrin alpha-v beta-8

Publications (2)

Publication Number Publication Date
BR112014003501A2 BR112014003501A2 (pt) 2017-03-01
BR112014003501B1 true BR112014003501B1 (pt) 2022-02-08

Family

ID=47715714

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014003501-6A BR112014003501B1 (pt) 2011-08-17 2012-08-17 Anticorpo humanizado que se liga especificamente à integrina alfa-v beta-8, seu uso na redução da sinalização de tgfbeta, composição farmacêutica, bem como método para detectar a presença de uma célula que expressa alfa-v beta-8

Country Status (13)

Country Link
US (1) US9492569B2 (cg-RX-API-DMAC7.html)
EP (1) EP2744823B1 (cg-RX-API-DMAC7.html)
JP (1) JP6093360B2 (cg-RX-API-DMAC7.html)
KR (1) KR102010098B1 (cg-RX-API-DMAC7.html)
CN (1) CN103857696B (cg-RX-API-DMAC7.html)
AU (1) AU2012296362B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014003501B1 (cg-RX-API-DMAC7.html)
CA (1) CA2846240C (cg-RX-API-DMAC7.html)
ES (1) ES2643397T3 (cg-RX-API-DMAC7.html)
MX (1) MX350335B (cg-RX-API-DMAC7.html)
RU (1) RU2614252C2 (cg-RX-API-DMAC7.html)
SG (1) SG2014014237A (cg-RX-API-DMAC7.html)
WO (1) WO2013026004A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103490A2 (en) * 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
ES2779412T3 (es) * 2014-06-17 2020-08-17 Medimmune Ltd Anticuerpos Alfa-V Beta-8 mejorados
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
CN109862913B (zh) 2016-09-29 2023-09-05 加利福尼亚大学董事会 用于免疫疗法的αvβ8整联蛋白复合物的中和抗体
EP3630185A4 (en) * 2017-05-30 2020-06-17 The Board of Trustees of the Leland Stanford Junior University TREATMENT OF A NEUROINFLAMMATIONAL DISEASE
CN112823167B (zh) 2018-09-07 2025-07-15 辉瑞大药厂 抗-αvβ8抗体和组合物及其用途
BR112021009325A2 (pt) * 2018-11-14 2021-09-14 Arch Oncology, Inc. Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
TWI854088B (zh) 2020-01-27 2024-09-01 英商梅迪繆思有限公司 用於治療腎臟疾病之抗αvβ8整聯蛋白抗體
WO2024056668A1 (en) * 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
KR20250167591A (ko) * 2023-03-31 2025-12-01 제넨테크, 인크. 항-알파 v 베타 8 인테그린 항체 및 사용 방법
WO2024258908A1 (en) * 2023-06-12 2024-12-19 University Of Washington De novo designed alpha (v) beta (8) integrin selective minibinder
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0575554A1 (en) * 1991-03-14 1993-12-29 Genentech, Inc. Novel beta integrin subunit
ATE244306T1 (de) * 1994-12-20 2003-07-15 Merck Patent Gmbh Monoklonaler antikörper gegen das alpha-v- integrin
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
WO2004043989A2 (en) * 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
KR101224235B1 (ko) * 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 il­9 항체 및 그의 용도
JP4653660B2 (ja) * 2003-09-04 2011-03-16 独立行政法人理化学研究所 TGF−β活性化制御領域の切断面を認識する抗体
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
US20110250203A1 (en) * 2008-08-29 2011-10-13 Symphogen A/S Anti-cd5 antibodies
BR112012003686B1 (pt) * 2009-08-19 2021-09-21 Merck Patent Gmbh Anticorpos monoclonais, seu uso para detecção de complexos de integrina em material ffpe, e polinucleotídeo
WO2011103490A2 (en) * 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY

Also Published As

Publication number Publication date
MX350335B (es) 2017-09-04
US20140271478A1 (en) 2014-09-18
KR20140054238A (ko) 2014-05-08
CN103857696B (zh) 2017-07-04
CA2846240C (en) 2021-01-12
AU2012296362A1 (en) 2014-03-13
MX2014001850A (es) 2014-12-08
WO2013026004A3 (en) 2013-06-13
AU2012296362B2 (en) 2017-06-29
KR102010098B1 (ko) 2019-08-13
WO2013026004A2 (en) 2013-02-21
EP2744823B1 (en) 2017-08-02
US9492569B2 (en) 2016-11-15
RU2014109928A (ru) 2015-09-27
JP2015501285A (ja) 2015-01-15
EP2744823A4 (en) 2015-08-12
RU2614252C2 (ru) 2017-03-24
JP6093360B2 (ja) 2017-03-08
ES2643397T3 (es) 2017-11-22
CN103857696A (zh) 2014-06-11
SG2014014237A (en) 2014-07-30
CA2846240A1 (en) 2013-02-21
BR112014003501A2 (pt) 2017-03-01
EP2744823A2 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
AU2012296362B2 (en) Antibodies that bind integrin alpha-v beta-8
US12110334B2 (en) Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
CN113939318A (zh) 抗体-药物缀合物的制剂
CN101820910B (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
JP5763105B2 (ja) 頭頸部扁平上皮癌の治療に使用されるcd44に対するモノクローナル抗体
BR112012020790B1 (pt) Anticorpo isolado anti-integrina alfavbeta8 e composição farmacêutica
JP2023511554A (ja) インテグリンαvβ8に結合する抗体およびその使用
HK1196971B (en) Antibodies that bind integrin alpha-v beta-8
HK1196971A (en) Antibodies that bind integrin alpha-v beta-8
US20260132217A1 (en) ANTI-sCD146 ANTIBODIES AND USES THEREOF
HK40008779A (en) NEUTRALIZING ANTIBODIES TO THE αVβ8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
HK40008779B (en) NEUTRALIZING ANTIBODIES TO THE αvβ8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/08/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2845 DE 15-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.